These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38924340)

  • 21. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sézary syndrome.
    Beylot-Barry M; Booken N; Weishaupt C; Scarisbrick J; Wu W; Rosen JP; Medley MC
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):311-316. PubMed ID: 35993803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
    Muszbek N; Remak E; Xin Q; McNamara L; Jones T
    J Comp Eff Res; 2023 Jul; 12(7):CER. PubMed ID: 37338181
    [No Abstract]   [Full Text] [Related]  

  • 23. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
    Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
    J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
    [No Abstract]   [Full Text] [Related]  

  • 24. [Mogamulizumab-associated rash: cutaneous T-cell lymphoma in complete remission].
    Leonhardt A; Maurer M; Flaig MJ
    Dermatologie (Heidelb); 2024 Oct; 75(Suppl 1):5-8. PubMed ID: 39278871
    [No Abstract]   [Full Text] [Related]  

  • 25. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
    Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
    Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
    Mukai M; Mould D; Maeda H; Narushima K; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.
    Trager MH; de Clippelé D; Ram-Wolff C; de Masson A; Vignon-Pennamen MD; Battistella M; Michel L; Bagot M; Dobos G
    Acta Derm Venereol; 2020 May; 100(10):adv00158. PubMed ID: 32449779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population Pharmacokinetic Modeling of Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma or Adult T-Cell Lymphoma.
    Mukai M; Maeda H; Narushima K; Mould DR; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):58-66. PubMed ID: 31840838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma.
    Blanchard G; Guenova E
    Br J Dermatol; 2022 Jan; 186(1):15-16. PubMed ID: 34988981
    [No Abstract]   [Full Text] [Related]  

  • 30. Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas.
    Caruso L; Castellino A; Dessì D; Flenghi L; Giordano A; Ibatici A; Massone C; Pileri A; Proietti I; Pupo L; Quaglino P; Rupoli S; Zinzani PL
    Cancer Manag Res; 2022; 14():3205-3221. PubMed ID: 36444356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.
    Numata T; Nagatani T; Shirai K; Maeda T; Mae K; Nakasu M; Saito M; Usuda T; Tsuboi R; Okubo Y
    Clin Exp Dermatol; 2018 Apr; 43(3):281-285. PubMed ID: 29327377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adult T-cell leukemia/lymphoma clinically confused with viral/drug skin eruptions and pathologically misinterpreted as mycosis fungoides/Sézary syndrome.
    AbdullGaffar B; Abdulrahman S
    J Cutan Pathol; 2021 Sep; 48(9):1103-1108. PubMed ID: 33354782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report.
    L'Orphelin JM
    Ther Adv Hematol; 2024; 15():20406207241235777. PubMed ID: 38456078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Persistent Effects of Mogamulizumab on Peripheral Blood Lesions after Treatment Completion in a Patient with Refractory Sézary Syndrome-A Case Report].
    Manabe M; Endo H; Inano N; Hagiwara Y; Nanno S; Koh KR
    Gan To Kagaku Ryoho; 2024 Aug; 51(8):833-835. PubMed ID: 39191715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression of CD8-positive Sézary syndrome from mycosis fungoides following dupilumab treatment.
    Fujii K; Yoshizaki A; Matsuoka A; Baba N; Ohshima K; Kanekura T
    Eur J Dermatol; 2024 Jun; 34(3):294-296. PubMed ID: 39015963
    [No Abstract]   [Full Text] [Related]  

  • 36. Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Grimm SE; Witlox W; Wolff R; Chalker A; Hiligsmann M; Wijnen B; Ahmadu C; Ryder S; Armstrong N; Duffy S; Syndikus I; Kleijnen J; Joore MA
    Pharmacoeconomics; 2022 May; 40(5):509-518. PubMed ID: 34664200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome.
    Molloy K; Vico C; Ortiz-Romero PL; Scarisbrick JJ
    Br J Dermatol; 2021 May; 184(5):978-981. PubMed ID: 33314065
    [No Abstract]   [Full Text] [Related]  

  • 39. Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.
    Roelens M; de Masson A; Andrillon A; Ram-Wolff C; Biard L; Boisson M; Mourah S; Battistella M; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2022 Jun; 186(6):1010-1025. PubMed ID: 35041763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mogamulizumab for Sézary syndrome: long-term remission with associated autoimmune haemolytic anaemia.
    Lé AM; Peixeiro R; Lau C; Teixeira MDA; Cabral R; Fernandes I
    Eur J Dermatol; 2024 Aug; 34(4):457-459. PubMed ID: 39193694
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.